MARKET RELEASE

28 March 2018

Antisense Therapeutics Limited

TRADING HALT

The securities of Antisense Therapeutics Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 3 April 2018 or when the announcement is released to the market.

Security Code: ANP

Dean Litis
PRINCIPAL ADVISER, LISTINGS COMPLIANCE (MELBOURNE)

Wednesday 28 March 2018

Dean Litis
Principal Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited

Email: dean.litis@asx.com.au

Dear Dean,

Request for Trading Halt for Antisense Therapeutics Limited

In accordance with ASX Listing Rule 17.1, the Directors of Antisense Therapeutics Limited ("the Company") request an immediate trading halt in respect of its securities (ASX Code: ANP).

In requesting the trading halt, the Company provides the following information:

- The trading halt is requested pending an institutional placement and entitlement issue;
- Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until the earlier of the release of an announcement to the market or the morning of Tuesday 3rd April 2018; and
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely,



Phillip Hains
Company Secretary

6-8 Wallace Avenue
Toorak, Victoria
Australia 3142

Antisense Therapeutics Limited
ABN 41 095 060 745

Phone: + 61 (0)3 9827 8999
Facsimile: + 61 (0)3 9827 1166

www.antisense.com.au